|
Beone Medicines is a global oncology company discovering and developing treatments for cancer, with a primary focus on hematology and solid tumors. The company's core franchise in chronic lymphocytic leukemia (CLL) includes the Bruton’s tyrosine kinase (BTK) inhibitor BRUKINSA (zanubrutinib), the B-cell lymphoma 2 (BCL2) inhibitor sonrotoclax, and the BTK chimeric degradation activation compound (BTK-CDAC) BGB-16673. Its solid tumor portfolio features the anti-PD-1 antibody TEVIMBRA (tislelizumab) and investigational assets including the CDK4 inhibitor BGB-43395, the B7-H4 antibody-drug conjugate BG-C9074, the GPC3-dependent 4-1BB bispecific T-cell engager BGB-B2033, the PRMT5 inhibitor BGB-58067, and the CEA ADC BG-C477. Beone Medicines operates an integrated model with in-house clinical development and manufacturing capabilities across the U.S., China, the UK, and Australia. The company serves markets in the U.S., Europe, Japan, Korea, and Brazil, and has established partnerships with Amgen, Novartis, and Celgene. Founded in 2010 by John V. Oyler and Xiaodong Wang, the company was formerly known as BeiGene. Summarised from the company's own disclosures, fiscal year ended Feb 2026 |
Industry Biotechnology | Homepage beonemedicines.com |
| Sector Healthcare | IR page ir.beonemedicines.com | |
|
Tags
oncology, hematology, solid tumors, btk inhibitors, bcl2 inhibitors, antibody-drug conjugates, bispecific antibodies, protein degraders, cll, mantle cell lymphoma, lung cancer, breast cancer, BRUKINSA, zanubrutinib, sonrotoclax, BGB-16673, TEVIMBRA, tislelizumab, BGB-43395, BG-C9074, BGB-B2033, BGB-58067, BG-C477, lifirafenib, pamiparib, BGB-3111, BeOne Care Foundation
|
Press page beonemedicines.com/newsroom |
Metrics
| Valuation | |
|---|---|
| Market cap | $ 602.148B |
| Market cap (USD) | $ 602.148B |
| P/E | 665.49 |
| PEG | — |
| P/BV | 103.45 |
| P/S | 91.14 |
| P/OCF | 378.66 |
| P/FCF | 415.49 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 7.5% |
| ROI | 5.3% |
| ROIC | 5.7% |
| Profit margin | 5.4% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | Yes |
| Revenue up 5y | Yes |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | Yes |
| Buying back stock | No |
| Diluting (TTM) | Yes |
| Debt/Equity | 18.5% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 38 |
| Quality score | 5.9% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.343B | 3.81B | 2.459B | 1.416B | 1.176B | 308.874M | 428.212M | 198.22M | 238.387M | 1.07M | 8.816M |
| Net profit | 286.933M | -644.786M | -881.708M | -2.004B | -1.413B | -1.597B | -948.628M | -673.769M | -93.105M | -119.217M | -57.102M |
| Free cash flow | 941.741M | -633.294M | -1.719B | -1.822B | -1.562B | -1.401B | -839.881M | -618M | -33.622M | -113.015M | -45.157M |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (USD) | — | 29.4M | 41.1M | 70.9M | 60.4M | 483M | 173M | 358M | 676M | 865M |
| ↳ YoY growth | +39.5% | +72.6% | -14.8% | +699.8% | -64.2% | +106.8% | +88.9% | +27.9% | ||
| ↳ 5y CAGR | +42.5% | +54.2% | +57.0% | +70.3% | ||||||
| Borrowings, current (USD) | — | 9.22M | 8.73M | 0.00 | 670M | 428M | 329M | 688M | 852M | 66.4M |
| Borrowings, non-current (USD) | 17.3M | 9.22M | 40.8M | 83.3M | 184M | 202M | 209M | 198M | 166M | 962M |
| Lease liabilities (USD) | — | — | 27.4M | 36.6M | 43.3M | 65M | 58.6M | 44.2M | 61.9M | 73.6M |
| Cash and deposits (USD) | 87.5M | 240M | 713M | 618M | 1.38B | 4.38B | 3.87B | 3.17B | 2.63B | 4.55B |
| Intangible assets (USD) | — | 7.25M | 7.17M | 5.85M | 5M | 46.7M | 40.6M | 57.1M | 51.1M | 62.7M |
| Right-of-use assets (USD) | — | 12.5M | 45.1M | 82.5M | 90.6M | 117M | 110M | 95.2M | 139M | 148M |
| Net debt (borrowings + leases - cash) (USD) | -70.2M | -221M | -663M | -498M | -485M | -3.68B | -3.27B | -2.24B | -1.55B | -3.45B |
| Cash flow detail | ||||||||||
| Operating cash flow (USD) | -89.5M | 12.8M | -548M | -750M | -1.28B | -1.3B | -1.5B | -1.16B | -141M | 1.13B |
| Purchases of property, plant and equipment (USD) | -23.5M | -46.4M | -70.3M | -89.6M | -118M | -263M | -325M | -562M | -493M | -186M |
| Purchases of intangible assets (USD) | 0.00 | 0.00 | -553,000 | 0.00 | 0.00 | -43.4M | 0.00 | -19.4M | -4.67M | -20M |
| Change in receivables (cash effect) (USD) | 0.00 | -29.4M | -11.6M | -29.8M | 10.4M | -423M | 304M | -188M | -329M | -165M |
| Change in inventories (cash effect) (USD) | 0.00 | -10.9M | -5.31M | -12.3M | -58.9M | -153M | -56.7M | -141M | -91.5M | -93.2M |
| Change in payables (cash effect) (USD) | 2.71M | 55.3M | 23.5M | 2.22M | 95.8M | 20M | -4.35M | 21.5M | 121M | 79.8M |
| Interest paid (cash effect) (USD) | -826,000 | -1.26M | -2.21M | -4.32M | -44.1M | -30M | -25.2M | -19.8M | -19.7M | -34.4M |
| Income taxes paid (cash effect) (USD) | -25,000 | -29.3M | -12.4M | -8.98M | -10.6M | -15.7M | -29.5M | -56M | -69.4M | -101M |
| Share-based compensation (USD) | 10.6M | 42.9M | 87.1M | 134M | 183M | 241M | 303M | 368M | 442M | 511M |
| Operating cash flow before change in receivables (USD) | -89.5M | 42.2M | -536M | -720M | -1.29B | -876M | -1.8B | -969M | 189M | 1.29B |
| Free cash flow (OCF - PPE - intangibles) (USD) | -113M | -33.6M | -619M | -840M | -1.4B | -1.61B | -1.82B | -1.74B | -638M | 922M |
| Income detail | ||||||||||
| Research and development expense (USD) | 98M | 269M | 679M | 927M | 1.29B | 1.46B | 1.64B | 1.78B | 1.95B | 2.15B |
| ↳ 5y CAGR | +119.1% | +111.6% | +85.9% | +71.6% | +43.6% | +21.2% | +16.1% | +10.6% | ||
| Total comprehensive income (USD) | -118M | -92.7M | -672M | -960M | -1.59B | -1.4B | -2.1B | -904M | -694M | 358M |
| Comprehensive income to owners (USD) | -118M | -92.6M | -672M | -958M | -1.58B | -1.4B | -2.1B | -904M | -694M | 358M |
| Provision for credit losses (USD) | — | — | — | — | 109,000 | 309,000 | -219,000 | — | — | — |
| Credit cost ratio (credit losses / average receivables) (%) | — | — | — | — | 0.2% | 0.1% | 0.1% | — | — | — |
| Reported | Feb 28, 2019 | Feb 28, 2019 | May 9, 2019 | Mar 2, 2020 | Feb 25, 2021 | Feb 28, 2022 | Feb 27, 2023 | Feb 27, 2025 | Feb 27, 2025 | Feb 26, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpMaterial events reported to the SEC on Form 8-K or 6-K, newest first. The link opens the filing itself on EDGAR. Announcements and reports published on HKEXnews, newest first, monthly and next-day returns, proxy forms and board-meeting notices included. The link opens the announcement on HKEXnews. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
Company History
Name and ticker changes, and re-registrations under a new regulatory id. When a ticker stopped being used is not recorded, so former tickers are undated.
| Date | Change | Detail |
|---|---|---|
| May 27, 2025 | Renamed | BEIGENE, LTD. → BEONE MEDICINES LTD. |
| — | Former tickers | BGNE |
ETFs Holding Beone Medicines Ltd.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| CANC | 3.18% | 18,669 | $ 6.713M | Aug 31, 2026 |
| SAGP | 1.63% | 57,500 | $ 1.249M | Jun 30, 2026 |
| PCCE | 1.12% | 800 | $ 17.382K | Jun 30, 2026 |
| CGGO | 0.85% | 240,864 | $ 99.065M | Nov 16, 2026 |
| CGGE | 0.82% | 64,959 | $ 26.717M | Nov 16, 2026 |
| CGIE | 0.70% | 41,231 | $ 16.958M | Nov 16, 2026 |
| CGNG | 0.68% | 48,251 | $ 19.845M | Nov 16, 2026 |
| FEMR | 0.64% | 37,464 | $ 1.011M | Jun 30, 2026 |
| EMEQ | 0.61% | 14,328 | $ 4.083M | Jun 30, 2026 |
| TMED | 0.40% | 322 | $ 91.76K | Jun 30, 2026 |
| FFEM | 0.36% | 711 | $ 224.683K | Jul 31, 2026 |
| HELX | 0.23% | 225 | $ 64.118K | Jun 30, 2026 |
| APIE | 0.19% | 6,192 | $ 2.227M | Aug 31, 2026 |
| DFAE | 0.18% | 311,330 | $ 16.182M | Nov 12, 2026 |
| DFSE | 0.15% | 8,670 | $ 884.576K | Nov 12, 2026 |
| AVSE | 0.15% | 7,703 | $ 318.867K | Nov 16, 2026 |
| TIER | 0.15% | 2,100 | $ 51.912K | Jul 31, 2026 |
| NTSE | 0.14% | 273 | $ 77.797K | Jun 30, 2026 |
| REMG | 0.13% | 6,600 | $ 143.397K | Jun 30, 2026 |
| AVEM | 0.11% | 744,667 | $ 27.651M | Nov 16, 2026 |
| FTLS | 0.10% | 6,527 | $ 0.00 | Nov 16, 2026 |
| DFEM | 0.10% | 61,403 | $ 8.52M | Nov 12, 2026 |
| DEHP | 0.09% | 2,501 | $ 350.283K | Nov 12, 2026 |
| JSTC | 0.08% | 586 | $ 241.016K | Nov 17, 2026 |
| DFAX | 0.02% | 44,007 | $ 2.434M | Nov 12, 2026 |